- Home
- NTLA vs AACT Comparison
NTLA vs AACT Comparison
Compare NTLA & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- AACT
- Stock Information
- Founded
- NTLA 2014
- AACT 2021
- Country
- NTLA United States
- AACT United States
- Employees
- NTLA N/A
- AACT N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AACT
- Sector
- NTLA Health Care
- AACT
- Exchange
- NTLA Nasdaq
- AACT Nasdaq
- Market Cap
- NTLA 794.5M
- AACT 697.5M
- IPO Year
- NTLA 2016
- AACT 2023
- Fundamental
- Price
- NTLA $9.20
- AACT $11.30
- Analyst Decision
- NTLA Buy
- AACT
- Analyst Count
- NTLA 20
- AACT 0
- Target Price
- NTLA $36.60
- AACT N/A
- AVG Volume (30 Days)
- NTLA 6.0M
- AACT 643.7K
- Earning Date
- NTLA 08-07-2025
- AACT 01-01-0001
- Dividend Yield
- NTLA N/A
- AACT N/A
- EPS Growth
- NTLA N/A
- AACT N/A
- EPS
- NTLA N/A
- AACT 0.36
- Revenue
- NTLA $45,569,000.00
- AACT N/A
- Revenue This Year
- NTLA N/A
- AACT N/A
- Revenue Next Year
- NTLA N/A
- AACT N/A
- P/E Ratio
- NTLA N/A
- AACT $31.27
- Revenue Growth
- NTLA N/A
- AACT N/A
- 52 Week Low
- NTLA $5.90
- AACT $10.65
- 52 Week High
- NTLA $28.18
- AACT $11.62
- Technical
- Relative Strength Index (RSI)
- NTLA 57.28
- AACT 45.02
- Support Level
- NTLA $8.00
- AACT $11.27
- Resistance Level
- NTLA $10.52
- AACT $11.32
- Average True Range (ATR)
- NTLA 0.67
- AACT 0.06
- MACD
- NTLA 0.15
- AACT -0.02
- Stochastic Oscillator
- NTLA 63.35
- AACT 14.67
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.